ליפיטור 80 מג Israeli - Kiebrania - Ministry of Health

ליפיטור 80 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

ליפיטור 10 מג Israeli - Kiebrania - Ministry of Health

ליפיטור 10 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

ליפיטור 10 מג Israeli - Kiebrania - Ministry of Health

ליפיטור 10 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

ליפיטור 20 מג Israeli - Kiebrania - Ministry of Health

ליפיטור 20 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 20 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

ליפיטור 20 מג Israeli - Kiebrania - Ministry of Health

ליפיטור 20 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 20 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

ביפוויט Israeli - Kiebrania - Ministry of Health

ביפוויט

vitamed pharmaceutical industries ltd - bifonazole - קרם - bifonazole 1 % - bifonazole - bifonazole - broad spectrum product for the treatment of fungal infections.

בטאקורטן קרם Israeli - Kiebrania - Ministry of Health

בטאקורטן קרם

trima israel pharmaceutical products maabarot ltd - betamethasone as valerate - קרם - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - for local treatment of inflammatory dermatoses and allergic skin conditions.

בטאקורטן משחה Israeli - Kiebrania - Ministry of Health

בטאקורטן משחה

trima israel pharmaceutical products maabarot ltd - betamethasone as valerate - משחה - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - for local treatment of inflammatory dermatoses and allergic skin conditions.

סומאברט 10 מג Israeli - Kiebrania - Ministry of Health

סומאברט 10 מג

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 10 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize igf-i concentrations or was not tolerated.

סומאברט 15 מג Israeli - Kiebrania - Ministry of Health

סומאברט 15 מג

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 15 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not narmalize igf-i concentrations or was not tolerated.